← Back to Search
Drug Release Rate Influences The Pharmacokinetics, Biodistribution, Therapeutic Activity, And Toxicity Of Pegylated Liposomal Doxorubicin Formulations In Murine Breast Cancer.
G. Charrois, T. Allen
Published 2004 · Chemistry, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The pharmacokinetics (PK), biodistribution (BD), and therapeutic activity of pegylated liposomal doxorubicin formulations with different drug release rates were studied in an orthotopic 4T1 murine mammary carcinoma model. The focus of these experiments was to study the effects of different release rates on the accumulation of liposomal lipid and doxorubicin (DXR) into the tumor and cutaneous tissues of mice (skin and paws). These tissues were chosen because the clinical formulation of pegylated liposomal doxorubicin (Caelyx)/Doxi) causes mucocutaneous reactions such as palmar-plantar erythrodysesthesia (PPE). Liposomes with different doxorubicin (DXR) leakage rates were prepared by altering liposome fluidity through changing the fatty acyl chain length and/or degree of saturation of the phosphatidylcholine component of the liposome. Liposomes with fast, intermediate, and slow rates of drug release were studied. The plasma PK of the liposomal lipid was similar for all formulations, while the plasma PK of the DXR component was dependent on the liposome formulation. Liposomal lipid accumulated to similar levels in tumor and cutaneous tissues for all three formulations tested, while the liposomes with the slowest rates of DXR release produced the highest DXR concentrations in both cutaneous tissues and in tumor. Liposomes with the fastest drug release rates resulted in low DXR concentrations in cutaneous tissues and tumor. The formulation with intermediate release rates produced unexpected toxicity that was not related to the lipid content of the formulation. The liposomes with the slowest rate of drug leakage had the best therapeutic activity of the formulations tested.
This paper references
Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer.
E. Moase (2001)
Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo.
T. Allen (1991)
Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs
A. Gabizon (2004)
Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl).
Dayan Ad (1996)
Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity.
G. Charrois (2003)
A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form
D. Waterhouse (2001)
Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor.
C. Aslakson (1992)
Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.
L. Mayer (1990)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
Openings between defective endothelial cells explain tumor vessel leakiness.
H. Hashizume (2000)
Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
H. Lim (1997)
Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia
A. López (1999)
Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
J. W. Cowens (1993)
Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
L. Mayer (1989)
Serum-induced leakage of liposome contents.
T. Allen (1980)
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
F. Muggia (1997)
Applied biopharmaceutics and pharmacokinetics
L. Shargel (1980)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
H. Maeda (2000)
Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times.
A. Gabizon (1989)
Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals
A. Gabizon (1997)
Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes
M. Bally (2004)
The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin.
G. Berry (1998)
Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity
G. Charrois (2003)
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.
D. Drummond (1999)
Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes
T. Harasym (1997)
Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes.
A. Gabizon (1992)
Processing of different liposome markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages.
J. T. Derksen (1987)
Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes.
M. Woodle (1992)
Vesicles of variable sizes produced by a rapid extrusion procedure.
L. Mayer (1986)
Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models.
S. Bandak (1999)
125I labelled inulin: a convenient marker for deposition of liposomal contents in vivo.
E. Sommerman (1984)
Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
T. Allen (1992)
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer.
E. Kim (2001)
Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues.
T. Allen (1989)
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.
A. Gabizon (1988)
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
A. Gabizon (1994)
Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.
M. Lotem (2000)
Ammonium Sulfate Gradients for Efficient and Stable Remote Loading of Amphipathic Weak Bases into Liposomes and Ligandoliposomes.
E. Bolotin (1994)
Cutaneous reactions to chemotherapy drugs: the art of consultation.
K. Remlinger (2003)
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
M. Ranson (1997)
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.
D. Papahadjopoulos (1991)
Pharmacokinetics of long-circulating liposomes
T. Allen (1995)
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
B. Uziely (1995)
An Improved Method for in Vivo Tracing and Imaging of Liposomes Using a Gallium 67-Deferoxamine Complex
A. Gabizon (1988)
This paper is referenced by
Biophysical characterization of lipid nanoparticles containing nucleic acid polymers as produced by microfluidic mixing
Alex Kar-Kei Leung (2014)
Designing a novel in vitro drug-release-testing method for liposomes prepared by pH-gradient method.
K. Nakamura (2012)
Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations.
M. J. W. Johnston (2008)
Triggered radiosensitizer delivery using thermosensitive liposomes and hyperthermia improves efficacy of radiotherapy: An in vitro proof of concept study
Helena C Besse (2018)
The Red clover necrotic mosaic virus capsid as a multifunctional cell targeting plant viral nanoparticle.
Dustin M. Lockney (2011)
Release Advantages of A Liposomal Dendrimer-Doxorubicin Complex, Over Conventional Liposomal Formulation of Doxorubicin
A. Papagiannaros (2007)
UNIVERSIDADE FEDERAL DOS VALES DO JEQUITINHONHA E MUCURI - UFVJM
J. L. Barbosa (2013)
A simple protocol for preparation of a liposomal vesicle with encapsulated plasmid DNA that mediate high accumulation and reporter gene activity in tumor tissue.
Torben Gjetting (2011)
Self-assembled nanostructures formed by phospholipids and anticancer drugs. Serum albumin-nanoparticle interactions
D. Pentak (2016)
Nanobiotechnology based therapies against Cancer: an update
Sibhghatulla Shaikh (2015)
Sonosensitive liposomes for ultrasound-mediated drug delivery
T. J. Evjen (2011)
Novel dual VES phospholipid self-assembled liposomes with an extremely high drug loading efficiency.
Yongpeng Hou (2017)
Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Jingxia Cui (2007)
Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency
Christina E. M. Schindler (2019)
Controlled release of a protein kinase inhibitor UCN-01 from liposomes influenced by the particle size.
Masahiro Yamauchi (2008)
Highly Efficient Encapsulation of Anionic Small Molecules in Asymmetric Liposome Particles
Myung Kyu Lee (2015)
NIOSOMES : A ROLE IN TARGETED DRUG DELIVERY SYSTEM
Soumya Singh (2013)
Self-assembled nanoparticles of cholesterol-conjugated carboxymethyl curdlan as a novel carrier of epirubicin.
L. Li (2010)
Sustained delivery of doxorubicin from thermogelling poly(PEG/PPG/PTMC urethane)s for effective eradication of cancer cells
X. J. Loh (2012)
Infusion of dye molecules into Red clover necrotic mosaic virus.
L. Loo (2008)
Therapeutic efficacy evaluation of 111in-VNB-liposome on human colorectal adenocarcinoma HT-29/luc mouse xenografts
W. C. Lee (2006)
Effect of Local Dual Frequency Sonication on Drug Distribution from Nanomicelles
H. Hasanzadeh (2010)
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
D. Drummond (2008)
Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed.
H. Ando (2015)
Development and Characterization of a Liposome Imaging Agent
Jinzi Zheng (2011)
Chitosan-decorated selenium nanoparticles as protein carriers to improve the in vivo half-life of the peptide therapeutic BAY 55-9837 for type 2 diabetes mellitus
L. Rao (2014)
Solid State NMR Characterization of Ibuprofen:Nicotinamide Cocrystals and New Idea for Controlling Release of Drugs Embedded into Mesoporous Silica Particles.
E. Skorupska (2017)
Propolis loaded liposomes: evaluation of antimicrobial and antioxidant activities
Ayşegül Aylin Aytekin (2019)
Development of a fast and efficient liposomal drug loading technology for poorly water soluble drugs : formulation, characterization, and potential applications
Wei-Lun Tang (2018)
Activation Approaches on Delivery of Imaging and Therapeutic Agents
M. A. Patel (2014)
Therapeutic efficacy of the combination of doxorubicin-loaded liposomes with inertial cavitation generated by confocal ultrasound in AT2 Dunning rat tumour model
Jean-Louis Mestas (2014)
Nanotechnological Applications in Cancer Treatment and Tumor Imaging
A. Erdoğan (2013)See more